🔎 Trials Near Me

Hjem › Marginalzone-lymfom › Massachusetts

Marginalzone-lymfom kliniske forsøg i Massachusetts

12 studier for Marginalzone-lymfom søger deltagere på steder i Massachusetts.

Byer i Massachusetts

Officiel studietekst (engelsk)

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

  • Dana Farber Cancer Institute (Data Collection and Specimen Analysis), Boston
  • Beth Israel Deaconess Medical Center (Data Collection Only), Boston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07231952

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05006716

Epco, Zanu, Ritux for R/R FL or MZL

  • Dana-Farber Cancer Institute, Boston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06563596

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

  • Lahey Clinic, Burlington
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT04840602

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07101328

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

  • Massachusetts General Hospital, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 16. mar. 2026 · NCT06026319

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

  • Beth Israel Deaconess Medical Center, Boston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 13. mar. 2026 · NCT06510309

Study of SGR-1505 in Mature B-Cell Neoplasms

  • Beth Israel Deaconess Medical Center, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. feb. 2026 · NCT05544019

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

  • Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 30. jan. 2026 · NCT04669171

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

  • University of Massachusetts Memorial Medical Center, Worcester
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 10. dec. 2025 · NCT05602363

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

  • Dana Farber Cancer Institute, Boston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 5. dec. 2025 · NCT06986174

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Worcester
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.